



**How to Diagnose and Treat
LYMPHOMA**

November 6-8, 2020

Chairpersons: C. Buske, C. Thieblemont, A. Younes

Friday, November 6

- 10:00-10:10 **Welcome**
- 10:10-12:05 **SESSION I – Hodgkin’s Disease**
Chairs: Andreas Engert (Cologne) and Camille Laurent (Toulouse)
- 10:10-10:15 Introduction
- 10:15-10:35 Diagnostics
The boundaries of Hodgkin Lymphoma (case-based lecture) Stefano Pileri (Milan)
- 10:35-10:55 First line Treatment
Early stages (case-based lecture) Marc André (Namur, Yvoir)
- 10:55-11:15 First line Treatment
Intermediate/Advanced stages (case-based lecture) Andreas Engert (Cologne)
- 11:15-11:35 Relapsed Disease (case-based lecture) Pier Luigi Zinzani (Bologna)
- 11:35-12:05 *Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)*
- 12:05-12:55 **INTERACTIVE CASES (5’ introduction + 3 cases of 10’+5’)**
- 12:55-13:45 **Lunch**
- 13:45-14:40 **DEBATE I: Is there still a role for combined modality therapy for early stage CHL?**
Chair: Marc André (Namur, Yvoir)
- 13:45-13:50 Introduction
- Audience votes “pro” or “con”*
- 13:50 -14:05 Pro Joachim Yahalom (New York)
- 14:05-14:20 Con Peter Johnson (Southampton)
- Audience votes again “pro” or “con”*
- 14:20-14:40 Discussion

14:40-15:40 **SATELLITE SYMPOSIUM**

New insights in WM & MCL treatment landscape

Chairs: Gilles Salles (New York), Jorge J. Castillo (Boston)

Speakers: Véronique Leblond (Paris), Martin H Dreyling (Munich), Jorge J. Castillo (Boston)

This educational symposium is organized and funded by Beigene.

15:45-17:40 **SESSION II – T-Cell Lymphoma**

Chairs: Catherine Thieblemont (Paris) and Pier Luigi Zinzani (Bologna)

15:45-15:50 Introduction

15:50-16:10 Diagnostics (case-based lecture)

Philippe Gaulard (Créteil)

16:10-16:30 First line treatment (case-based lecture)

Owen O'Connor (New York)

16:30-16:50 Salvage treatment (case-based lecture)

Pier Luigi Zinzani (Bologna)

16:50-17:10 How clinical trials and the latest update of the WHO classification are shaping current and future therapies for T-cell lymphoma including the use of stem cell transplant – Towards more subtype-specific approaches?

Francesco d'Amore (Aarhus)

17:10-17:40 *Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)*

17:40-17:50 **Coffee break**

17:50-18:55 **ROUNDTABLE I – Future directions in T-Cell Lymphoma**

Chair: Camille Laurent (Toulouse)

17:50-17:55 Introduction

17:55-18:15 Title TBA

Ghandi Laurent Damaj (Caen)

18:15-18:35 Title TBA

Gerald Wulf (Göttingen)

18:35-18:55 Discussion Q & A

18:55-19:55 **5 Simultaneous Meet the Expert sessions:**

1. Circulating free DNA

Davide Rossi (Bellinzona)

2. Pet scan in lymphoma

Michel Meignan (Créteil)

3. Artificial intelligence for the diagnosis on lymphoma

Camille Laurent (Toulouse)

4. Follicular lymphoma

Gilles Salles (New York)

5. Car T-cell

Stephen Schuster (Philadelphia)

11:00-12:55 **SESSION IV – Follicular Lymphoma**
Chairs: Christian Buske (Ulm) and Franck Morschhauser (Lille)

11:00-11:05 *Introduction*

11:05-11:25 Diagnostics (case-based lecture) Wolfram Klapper (Kiel)

11:25-11:45 First line (case-based lecture) Stefano Luminari (Modena)

11:45-12:05 Salvage treatment (case-based lecture) Franck Morschhauser (Lille)

12:05-12:25 Challenges in FL – POD24 (case-based lecture) Emmanuel Bachy (Lyon)

12:25-12:55 *Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)*

12:55-14:30 **Lunch**

13:30-14:30 **SATELLITE SYMPOSIUM**

Immunotherapy: the new cornerstone of lymphoma care

Chair: Stefano Luminari (Reggio Emilia)

Speakers: Stefano Luminari (Reggio Emilia), Andrew Davies (Southampton) and Marc André (Namur)

This educational symposium is organized and funded by Celgene | A Bristol Myers Squibb Company

14:35-15:35 **Poster Walks**

15:35-16:30 **DEBATE II: Can we avoid chemotherapy in FL?**

Chair: Gilles Salles (New York)

15:35-15:40 *Introduction*

Audience votes “pro” or “con”

15:40-15:55 Pro

Nathan Fowler (Houston)

15:55-16:10 Con

Umberto Vitolo (Turin)

Audience votes “pro” or “con”

16:10-16:30 *Discussion*

16:30-16:40 **Coffee break**

16:40-18:15 **SESSION III – Rare Lymphomas – Marginal Zone Lymphoma and Waldenström Macroglobulinemia**

Chairs: Catherine Thieblemont (Paris) and Christian Buske (Ulm)

16:40-16:45 *Introduction*

16:45-17:05	Diagnostics (case-based lecture)	Maurilio Ponzoni (Milan)
17:05-17:25	Waldenström macroglobulinemia (case-based lecture)	Jorge J. Castillo (Boston)
17:25-17:45	MZL (case-based lecture)	Emanuele Zucca (Bellinzona)
17:45-18:15	<i>Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)</i>	
18:15-19:20	ROUNDTABLE II – Where to go in rare B-Cell Lymphomas Chair: Emanuele Zucca (Bellinzona)	
18:15-18:20	<i>Introduction</i>	
18:20-18:40	Marginal Zone Lymphoma case	Alexander Grunenberg (Ulm)
18:40-19:00	What we can learn from a single case of ENMZL with Multiple Mucosal Sites presentation?	Izidore S. Lossos (Miami)
19:00-19:20	<i>Discussion</i>	

Sunday, November 8

09:30-11:25	SESSION V – Mantle Cell Lymphoma Chairs: Olivier Hermine (Paris) and Elias Campo (Barcelona)	
09:30-09:35	<i>Introduction</i>	
09:35-09:55	Diagnostics (case-based lecture)	Elias Campo (Barcelona)
09:55-10:15	First line treatment (case-based lecture)	Steven Le Gouill (Nantes)
10:15-10:35	Salvage treatment (case-based lecture)	Martin H. Dreyling (Munich)
10:35-10:55	BTK failures (case-based lecture)	Olivier Hermine (Paris)
10:55-11:25	<i>Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)</i>	
11:25-12:15	INTERACTIVE CASES (5' introduction + 3 cases of 10'+5')	
12:15-13:05	Lunch	
13:05-15:00	SESSION VI – Diffuse Large B-Cell Lymphoma Chairs: Catherine Thieblemont (Paris) and Davide Rossi (Bellinzona)	
13:05-13:10	<i>Introduction</i>	
13:10-13:30	Diagnostics (case-based lecture)	Thierry Molina (Paris)*

13:30-13:50	First line (case-based lecture)	Andy Davies (Southampton)
13:50-14:10	Relapse (case-based lecture)	Jason Westin (Houston)
14:10-14:30	CAR – T cells (case-based lecture)	Stephen Schuster (Philadelphia)
14:30-15:00	<i>Discussion Q & A (a 10-minute brief oral communication may be integrated before the discussion)</i>	
15:00-15:45	Key Note Lecture: Biology and New Targets in DLBCL	Riccardo Dalla Favera (New York)
15:45-15:50	<i>Discussion</i>	

15:50-16:50 **SATELLITE SYMPOSIUM**
How I treat relapsed/refractory disease – DLBCL and CLL
Chair: Gilles Salles (New York)
Speakers: Marie-Jose Kersten (Amsterdam), Kieron Dunleavy (Washington), Michael Hallek (Cologne)
Astrid Pavlosky (Buenos Aires)

This educational symposium is organized and funded by Lymphoma Hub

16:55-17:50 **DEBATE III: Do we still need ASCT in MCL?**
Chair: Olivier Hermine (Paris)

16:55-17:00 *Introduction*

Audience votes “pro” or “con”

17:00-17:15 Pro

Marco Ladetto (Alessandria)

17:15 -17:30 Con

Speaker TBA*

Audience votes “pro” or “con”

17:30-17:50 *Discussion*

17:50-18:00 **Coffee break**

18:00-19:35 **SESSION VII – Novel Therapeutic Concepts in B-Cell Lymphomas**
Chair: Corinne Haioun (Créteil)

18:00-18:05 *Introduction*

18:05-18:25 Biomarker-Driven Mechanism-Based Combinations

Laura Pasqualucci (New York)

18:25-18:45 Next generation CAR-T cells (case-based lecture)

Renier Brentjens (New York)

18:45-19:05 Checkpoint Inhibitors and bispecifics (case-based lecture)

Stephen Ansell (Rochester)

19:05-19:35 *Discussion Q & A (a 10-minute brief oral communication may be integrated before the panel discussion)*

19:35-19:40 *Closing Remarks*

MEETING CLOSURE

* *Speakers TBA*